FIELD: medicine, pharmaceutics.
SUBSTANCE: there is offered a retinoprotective agent. The agent represents 4-methyl-2,6-diisobornylphenol and prevents epitheliocytus neurosensorius destruction.
EFFECT: means promotes a complete integrity of the retinal inner nuclear layer neurons from the damaging action of permanent prolonged hyperglycemia.
5 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
MEDICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2014 |
|
RU2555335C9 |
ANTI-ISCHEMIC DRUG | 2012 |
|
RU2499593C1 |
NEUROPROTECTOR | 2009 |
|
RU2406488C1 |
MEDICATION INCREASING BRAIN BLOOD FLOW | 2007 |
|
RU2351321C1 |
AGENTS WITH HEMORHEOLOGICAL, ANTIAGGREGANT AND ANTITROMBOGENIC ACTIVITY | 2007 |
|
RU2347561C2 |
AGENT RELIEVING POSTINFARCTION MYOCARDIAL REMODELING | 2020 |
|
RU2740895C1 |
SULPHUR-CONTAINING 2,6-DIISOBORNYLPHENOL DERIVATIVES | 2014 |
|
RU2568437C1 |
2,6-DIISOBORNYLPHENOLS | 2011 |
|
RU2502719C2 |
DRUG WITH COMPLEX PHARMACOLOGICAL EFFECT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, CORRECTION OF CEREBRAL CIRCULATION DISORDERS, TREATMENT OF CONSEQUENCES OF CEREBROVASCULAR DISEASES (OPTIONS) | 2019 |
|
RU2757874C1 |
HYDROPHILIC CONJUGATE OF HYDROXYETHYL STARCH AND 2,6-DIISOBORNYL-4-METHYLPHENOL | 2012 |
|
RU2497828C1 |
Authors
Dates
2010-12-20—Published
2009-05-06—Filed